Epidemiological profile of patients with prostatic neoplasia at an oncological hospital of SUS, Brazil

Abstract

Objective: To identify the epidemiological characteristics of patients with prostate cancer and evaluate the treatment with Eligard^® monthly, quarterly and semiannually according to efficacy and tolerance in HCM from January 2007 to July 2018. Methodology: Epidemiological, descriptive, retrospective, cross-sectional and quantitative research through the review of medical records . The population 932 patients with prostate neoplasia, treated at Cristiano Varella Foundation - HCM, MG state, Brazil, adult men (≥18 years old), with indication for Eligard^® in monthly (7.5 mg) (n=115), quarterly (22.5 mg) (n=637) and semiannual (45 mg) (n=180) dosage. Results: Median age was 72 years (65-78). Median time since diagnosis was 8.5 months, with 598 (64.2%) of patients with a diagnosis of 12 months or less, and 158 (17%) with time since diagnosis of more than 4 years. The majority (63.4%) had low education, were married (69.9%) and non-white (66.41% black + brown).  Regarding occupation, 541 (58.05%) are retired 148 (15.88%) and rural workers. Much of the information collected in the medical records about housing was not available 464 (49.8%), but 318 (34.12%) of the patients own their own homes. As for transportation, most 877 (94.1%) have the vehicles of the municipal health departments as their main means of transportation, which corroborates the information of low per capita income, low education, that is, low socioeconomic structure. All patients being treated at HCM with prostate cancer (100%) have support from the municipal health secretariats, the Basic Health Units, and also from the hospital itself. Regarding the nutritional status of patients, 754 (80.9%) have good nutrition (eutrophic), only 84 (9.02) were malnourished and 49 (5.22%) were obese. As for prevention (PSA exams), 444 subjects (42.4%) reported having had such an exam. Slightly more than 30% had a family history of cancer, and the same proportion for smokers and drinkers. Conclusions: Epidemiological characteristics (average age 75 years, non-white, married, with low education, retired, rural workers, depend on the support of the Health Departments of their municipalities, low per capita income, most have their own homes, are treated by SUS, do not smoke, do not drink, no family history); and clinical (most with stages II and III, treated with radiotherapy, comorbidities cardiovascular diseases, and adverse events considered the treatment itself). The results obtained allowed us to verify the efficacy of the hormone (Eligard^® ), a LHRH agonist used in the treatment of patients with this neoplasm, in all stages. The tolerability of the patients regarding this medication was also verified, with very satisfactory results in approximately 99% of all patients.

DOI: https://doi.org/10.56238/colleinternhealthscienv1-056